Evaluation of Alisporivir for the Treatment of Hospitalised Patients With Infections Due to SARS-CoV-2 (COVID-19)

NCT04608214 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

26

Enrollment

OTHER

Sponsor class

Conditions

SARS-CoV-2

Interventions

DRUG: Alisporivir
OTHER: Standard of care (SOC)

Sponsor

Assistance Publique - Hôpitaux de Paris

Collaborators

[object Object]